天堂国产午夜亚洲专区-少妇人妻综合久久蜜臀-国产成人户外露出视频在线-国产91传媒一区二区三区

當(dāng)前位置:主頁(yè) > 醫(yī)學(xué)論文 > 腫瘤論文 >

短程放療聯(lián)合替莫唑胺在老年膠質(zhì)母細(xì)胞瘤患者中的生存獲益分析

發(fā)布時(shí)間:2018-02-25 23:35

  本文關(guān)鍵詞: 老年 輔助治療 膠質(zhì)母細(xì)胞瘤 預(yù)后 出處:《廣東醫(yī)學(xué)》2017年01期  論文類型:期刊論文


【摘要】:目的探討短程放療聯(lián)合替莫唑胺(TMZ)方案在術(shù)后KPS評(píng)分較差的老年膠質(zhì)母細(xì)胞瘤(GBM)患者治療中的生存獲益情況。方法回顧分析行完整切除但術(shù)后KPS評(píng)分不佳的新診斷老年GBM患者71例,對(duì)不同MGMT狀態(tài)下各輔助治療方案進(jìn)行生存分析和比較。結(jié)果 71例患者年齡65~85歲,平均(71.10±5.19)歲,其中男50例,年齡(71.36±5.35)歲,女21例,年齡(70.48±4.90)歲;其中62例在隨訪截止日期前死亡,總體平均生存期(OS)(11.92±0.51)個(gè)月,2年生存率0;接受短程同步放化療聯(lián)合TMZ輔助治療組平均生存期顯著提高(P=0.002),與單純短程放療組相比差異性最大(P=0.001),而單純短程放療與單純TMZ輔助治療組之間OS差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);術(shù)后免疫組化MGMT陰性表達(dá)組患者更能從短程同步放化療聯(lián)合TMZ輔助化療中獲得生存獲益(P=0.004)。結(jié)論對(duì)于≥65歲接受腫瘤切除后功能狀態(tài)不佳的老年GBM患者,短程同步放化療聯(lián)合TMZ輔助治療可能是一種能獲得更多生存獲益的術(shù)后輔助治療方案,在MGMT啟動(dòng)子甲基化患者中,這種獲益優(yōu)勢(shì)更加明顯。
[Abstract]:Objective to investigate the survival benefits of short-course radiotherapy combined with temozolidomide in the treatment of elderly patients with glioblastoma with poor KPS score after operation. Methods New diagnosis with complete resection but poor postoperative KPS score was retrospectively analyzed. 71 elderly patients with GBM, Results 71 patients (50 males, 71.36 鹵5.35) and 21 females (70.48 鹵4.90) years old died before the deadline of follow-up, and 71 patients were 65 ~ 85 years old with an average age of 71.10 鹵5.19 years, including 50 males (71.36 鹵5.35) years old and 21 females (70.48 鹵4.90) years old. The overall mean survival time was 11.92 鹵0.51 months and the 2-year survival rate was 0. The mean survival time of the patients receiving short course radiotherapy and chemotherapy combined with TMZ adjuvant therapy was significantly higher than that of the simple short course radiotherapy group, and the difference was greatest compared with that of the simple short course radiotherapy group, while that of the simple short course radiotherapy group was higher than that of the simple TMZ group. There was no significant difference in OS between adjuvant treatment groups (P 0.05), and the survival benefit of patients with negative expression of immunohistochemical MGMT was more likely to be obtained from short course simultaneous radiotherapy and chemotherapy combined with TMZ adjuvant chemotherapy. Conclusion for patients 鈮,

本文編號(hào):1535651

資料下載
論文發(fā)表

本文鏈接:http://www.sikaile.net/yixuelunwen/zlx/1535651.html


Copyright(c)文論論文網(wǎng)All Rights Reserved | 網(wǎng)站地圖 |

版權(quán)申明:資料由用戶7bc63***提供,本站僅收錄摘要或目錄,作者需要?jiǎng)h除請(qǐng)E-mail郵箱bigeng88@qq.com